KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cvs Health (CVS) Other Non-Current Assets (2016 - 2025)

Cvs Health (CVS) has disclosed Other Non-Current Assets for 17 consecutive years, with $5.1 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets rose 6.8% year-over-year to $5.1 billion, compared with a TTM value of $5.1 billion through Dec 2025, up 6.8%, and an annual FY2025 reading of $5.1 billion, up 6.8% over the prior year.
  • Other Non-Current Assets was $5.1 billion for Q4 2025 at Cvs Health, down from $5.2 billion in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $5.2 billion in Q1 2025 and bottomed at $908.0 million in Q4 2022.
  • Average Other Non-Current Assets over 5 years is $4.5 billion, with a median of $4.8 billion recorded in 2021.
  • The sharpest move saw Other Non-Current Assets plummeted 80.74% in 2022, then surged 413.22% in 2023.
  • Year by year, Other Non-Current Assets stood at $4.7 billion in 2021, then tumbled by 80.74% to $908.0 million in 2022, then soared by 413.22% to $4.7 billion in 2023, then grew by 2.85% to $4.8 billion in 2024, then increased by 6.8% to $5.1 billion in 2025.
  • Business Quant data shows Other Non-Current Assets for CVS at $5.1 billion in Q4 2025, $5.2 billion in Q3 2025, and $5.2 billion in Q2 2025.